American pharmaceutical executives thought they could treat global drug development like any other outsourced supply chain. For decades, they moved clinical trials overseas quietly. They chased faster enrollment, cheaper data, and fewer regulatory hurdles. But that long era of operating under the radar just hit a brick wall in Washington.
A bipartisan group of lawmakers has opened a sweeping national security probe into five of the largest drugmakers in the United States. Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb are all in the crosshairs. The House Select Committee on the Chinese Communist Party wants answers, and they want them fast.
The committee sent letters giving these massive corporations until July 17 to hand over internal records. Congress wants to see the exact details of how these firms vet trial locations, protect intellectual property, and ensure ethical safety standards inside China. This is not a routine regulatory check. It is a fundamental questioning of how American healthcare companies do business with an adversarial foreign power.
The Shocking Numbers Behind the Investigation
When you look at the sheer volume of clinical testing done in China, you understand why lawmakers are sounding the alarm. This is not about a few isolated experiments. It represents a systemic reliance on Chinese medical infrastructure.
Consider Merck. Since 2005, the New Jersey-based pharmaceutical giant has sponsored or collaborated on 224 clinical studies inside China. The committee highlights that at least 40 of those trials took place at medical centers and hospitals directly affiliated with the People's Liberation Army. Another 31 trials were conducted in the Xinjiang region.
AbbVie shows a similar pattern. The Illinois-based drugmaker has backed more than 100 clinical studies in China since 2007. Out of those, 16 occurred at Chinese military centers and 17 were located in Xinjiang.
The letters state clearly that there is no current evidence showing these companies broke the law. But that is missing the point. The issue is that doing business in these specific areas carries massive national security risks and severe ethical liabilities that corporate boards chose to ignore because the financial savings were too good to pass up.
Military Exploitation of Biotech Data
Why does it matter if a drug trial happens in a military hospital? For years, Western companies viewed Chinese military medical centers simply as high-capacity facilities capable of processing thousands of patients quickly. Washington sees them as research arms of the Chinese state designed to absorb foreign technology.
When American companies run trials at these hospitals, they do not just test pills. They hand over massive amounts of genetic information, advanced biotechnology protocols, and proprietary research methodologies. Under China's national security laws, any data generated within its borders can be accessed by the government.
Lawmakers argue that this setup puts valuable biotechnology intellectual property at direct risk of being stolen or absorbed by the Chinese military. The line between civilian medicine and military application in China does not exist. It is a concept known as military-civil fusion. If a breakthrough cancer treatment or genetic therapy relies on research conducted in a military lab, that knowledge belongs to the state. American firms have essentially been subsidizing the research capabilities of a foreign military under the guise of corporate efficiency.
The Ethical Blind Spot in Xinjiang
The geographic choice of these trial sites makes the corporate defense even tougher. Xinjiang is the region where the Chinese government has carried out a brutal campaign against Uyghurs and other ethnic and religious minorities. The U.S. government has officially labeled these actions a genocide.
The committee letters raise horrifying questions about how these trials obtained informed consent. Western clinical trials rely on the absolute certainty that participants are volunteering freely. In a highly militarized surveillance state where entire populations face arbitrary detention, true informed consent is practically impossible.
Internal Chinese research documents have already shown significant flaws in how patients give consent at these regional sites. Lawmakers pointed to the spirit of the Uyghur Forced Labor Prevention Act of 2021. While that specific law targets physical manufacturing supply chains, its underlying principle applies to medicine. American money and research should not touch regions where forced compliance is standard practice. Pharma companies looked at the cheap cost of running trials in Xinjiang and ignored the human toll.
The Global Shift in Early Stage Drug Development
This congressional pushback comes as Washington watches China rapidly capture the global market for medical innovation. The numbers reveal a dramatic shift in where new drugs are born.
In 2015, the United States controlled 48% of global early-stage drug development programs. China held a mere 8% share. By 2024, the playing field completely changed. The American share slipped down to about 37%, while China's portion skyrocketed to more than 32%.
Beijing did not achieve this by accident. They used a deliberate mix of sweeping regulatory overhauls, heavy state subsidies, and loose ethical oversight to turn their country into the cheapest and fastest place on earth to test experimental treatments on humans.
American executives took the bait. Running an early-stage human trial in the West involves years of strict review boards, high participant compensation, and meticulous administrative tracking. Moving those operations to China slashed timelines and saved millions of dollars per molecule. But that shortcut created a massive structural vulnerability for the American healthcare industry.
How the Biosecure Act Changes Everything
This latest investigation is part of a much larger legislative web tightening around international biotechnology. The Biosecure Act has already restricted federal agencies from doing business with specific foreign biotech entities deemed security risks.
The era of unrestricted corporate globalization in medicine is officially over. Congress is signaling that it will scrutinize companies that already have deep footprints in China, rather than just blocking future partnerships. If your corporate revenue depends on intellectual property verified in Chinese military labs, your entire business model is exposed to sudden regulatory shutdown.
Immediate Steps for the Biotech Sector
Companies cannot wait for the July 17 deadline to see how this plays out. The scrutiny will only expand to smaller biotechs and academic institutions.
First, executives must audit every single historical and active trial site in their portfolio. If a facility has any ties to the People's Liberation Army or operates in sensitive regional provinces, those operations need immediate wind-down plans.
Second, legal teams must re-evaluate data storage and transfer protocols. Relying on local Chinese servers means giving up data sovereignty. Moving trial data out of China is already difficult due to Beijing's data export laws, creating a dual-sided trap where Washington demands security and Beijing demands access.
Finally, the industry must rebuild domestic and regional clinical infrastructure. Testing must move back to the United States or to trusted allied nations, even if it increases the initial cost of drug development. The alternative is facing congressional subpoenas, lost intellectual property, and reputational ruin.
